Angiodynamics Inc. (ANGO)
ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation
AngioDynamics expands NanoKnife's EU indications to liver, pancreas, kidney and prostate tumors, broadening its oncology reach and growth runway.
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics: Growth Remains Under The Radar
AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improvement, especially in Med Tech, is critical for rerating; legacy Med Device business remains a headwind to sentiment. Recent clinical data for AlphaVac and NanoKnife support further adoption, while Auryon continues steady share gains in a competitive atherectomy market.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
